Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model

Mengyang Zhang¹,² · Changcheng Luo¹,² · Kai Cui¹,² · Tao Xiong¹,² · Zhong Chen¹,²

Received: 5 September 2019 / Accepted: 8 January 2020 / Published online: 21 January 2020 © The Author(s) 2020

Abstract

Objective Inflammation plays an important role in the development of benign prostatic hyperplasia (BPH). The aim of the present study was to reference the study of the pathological changes in the prostate gland of rats with experimental autoimmune prostatitis (EAP), for the development of experimental models of BPH.

Methods Experimental autoimmune prostatitis was induced in rats by the intradermal injection of rat prostate antigen with immunoadjuvants. In case of the positive BPH group, BPH was induced by the subcutaneous injection of testosterone propionate. At the end of the 45-day model period, prostate weights were measured, and the histopathological analysis of the prostate glands was performed. The levels of cytokines, TGF-β1/RhoA/ROCK signals, and the oxidative stress status were also examined.

Results Rats from the EAP group had a higher histological score than those from the control group. Compared to the samples from rats in the hormone-induced group, those from the EAP group showed a more pronounced increase in the size of the stromal compartment; this was characterized by the formation of reactive stroma and the deposition of a greater amount of extracellular matrix (ECM). Significant increases in the numbers of CD3-positive cells and CD68-positive cells, as well as a significant upregulation in the cytokine levels, and an increase in the TGF-β1 levels and activation of RhoA/ROCK signaling, were observed in the samples from rats in the EAP group.

Conclusion Chronic inflammation can induce BPH in rats via EAP model method. When performing drug experiments on the stroma compartments of BPH, the use of the EAP model is a recommendation of the authors based on this study.

Keywords Animal models · Inflammation · Benign prostatic hyperplasia · Oxidative stress

Introduction

Benign prostate hyperplasia (BPH) is a common benign disease in old men. The incidence of the gross enlargement of the prostate gland has been reported to be 40% in 70-year-old men, and microscopic foci of the prostate gland are present in up to 80% of these men [1]. BPH is a multifactorial disease; androgens, estrogens, stromal–epithelial interactions, growth factors, and neurotransmitters may play a role, either singly or in combination, in the etiology of the hyperplastic process [2]. In recent years, it has been considered that inflammation is not just an occasional concomitant occurrence accompanying BPH, but instead, plays a key role in its etiology [3]. This is manifested by the high incidence of inflammation that has been found in excised BPH samples [4], and the degree of inflammation has shown a significant correlation with the severity of BPH [5-7]. BPH has been hypothesized to be an immune-mediated inflammatory disease, and inflammation may directly contribute to prostate growth [8].

At present, the hormone-induced animal model of BPH is mainly used for BPH-related studies. Indeed, testosterone plays an essential role in the development of BPH. In 1976,
Walsh and Wilson [9] first reported the successful use of hormones in castrated dogs to induce a BPH model. Based on their research, the animals currently used as models in many BPH drug therapy experiments are predominantly rats, and the model method is based on large doses of androgen, with castration or no castration, and androgen alone or a combination of estrogen and androgen [10–13]. However, the serum testosterone level of humans decreases with age [14]; hence, large exogenous doses of testosterone contradict the natural evolution of BPH. The hormone-induced models may thus, not fully represent the true nature of BPH.

To expand the scope of the model methods of BPH, other causes of BPH, such as inflammation, should be considered for the induction of BPH models. To mimic the appearance of inflammation with BPH, which is consistent with its natural evolution, we attempted to induce chronic inflammation in rats to investigate the pathological changes of the prostate gland and the related underlying mechanisms.

Material and methods

Animals and experimental design

A total of 36 male Sprague–Dawley rats (9 weeks old, 250–300 g) were supplied by the Laboratory Animal Center of the Tongji Medical College, Huazhong University of Science and Technology. The rats were housed in individual cages in a room maintained at 20–26 °C with a relative humidity of 35–75%; they were subjected to an alternating 12-h light–dark cycle (8:00 a.m. and 8:00 p.m.). The animals had free access to food and water. All procedures involving the animals were approved by the Institutional Animal Care and Use Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Hubei, China). After 7 days of acclimatization, the rats were randomly divided into four groups (n = 9 per group): (1) normal control group (NC), (2) testosterone-induced BPH model group (TI), (3) EAP group, and (4) prostate antigen supply group (they were sacrificed to obtain antigens for injecting the rats in the EAP group).

The induction of EAP was performed according to Zhou’s [15] method. The nine rats in group 4 were sacrificed by cervical dislocation and the prostate tissues were obtained and homogenized in 0.5% TritonX-100 (Beyotime Biotechnology, Shanghai, China); the homogenates were maintained in an ice water bath. They were then centrifuged at 10,000g for 30 min at 4 °C and the supernatants were separated. The protein concentrations in the supernatants were assayed by the BCA (bicinchoninic acid) assay (Multisciences Biotechnology Co. Ltd., Hangzhou, China) and diluted to concentrations of 10 mg/ml with 0.1 mol/L PBS buffer (pH 7.2). The nine rats in the EAP group were anesthetized by the intraperitoneal injection of pentobarbital (40 mg/kg). Then, they were intraperitoneally injected with 0.5 ml of Pertussis–Diphtheria–Tetanus vaccine (Wuhan Institute of Biological Products, Wuhan, Hubei, China). Next, a total of 1.0 ml of rat prostate protein extract and FAC (Freund's Adjuvant Complete; Sigma-Aldrich, MO, USA) emulsion (1:1) was injected subcutaneously into their necks, inner thighs, backs, or hind limbs. The rats in the EAP group were immunized twice, i.e., on day 0 and day 30. The rats in the TI group were injected subcutaneously with 5 mg/kg testosterone propionate (Solarbio Science & Technology Co. Ltd., Beijing, China) (dissolved in corn oil) daily for 45 days. The rats in the NC group did not undergo any treatment. After 45 days, the rats were sacrificed, and the ventral lobes of their prostate glands were quickly removed. One-third of the bilateral ventral lobes were fixed with 4% paraformaldehyde (Beyotime Biotechnology), and the remaining tissues were frozen at −80 °C.

H&E staining, Masson's trichrome staining, hexamine silver staining, immunohistochemical (IHC) staining, and immunofluorescence (IF) staining

The 4% paraformaldehyde-fixed prostate tissue samples from rats in each group were subjected to paraffin embedding and sectioned at a thickness of 5 μm. The tissue sections were subjected to hematoxylin–eosin (H&E) staining, Masson's trichrome staining, and hexamine silver staining using standard procedures, and examined under a light microscope. IHC staining was performed as previously described [16]. The sections were incubated with primary antibodies against Ki-67 (1:500; Affinity Biosciences, OH, USA) and transforming growth factor β1 (TGF-β1) (1:400; Proteintech Group, Wuhan, China) at 37 °C for 1 h. Then, they were treated with a biotinylated secondary antibody according to the standard protocol. For IF staining, the sections were washed and incubated with antibodies specific for alpha smooth muscle actin (α-SMA) (1:200; Affinity Biosciences) overnight at 4 °C, and then with donkey anti-rabbit IgG (Life Technologies; Thermo Fisher Scientific, Rockford, IL, USA) for 1 h in the dark at room temperature. The slides were mounted by adding DAPI-Fluoromount-G (Southern Biotechnology Associates, Inc., Birmingham, AL) and examined using a fluorescence microscope (Olympus, Tokyo, Japan).

Grading of the inflammation degree

The prostate samples were graded according to the degree of inflammation: mild, inflammatory foci constituted by 7–14 mononuclear cells; moderate, inflammatory foci constituted by 15–29 mononuclear cells; severe, inflammatory foci constituted by 30 or more mononuclear cells.
Semi-quantitative assessment of the histopathologic findings in the prostate samples

We used a chart score protocol that was established by Scolnik [17] and then improved by Golomb [18] to perform a better evaluation of the ventral prostate hyperplastic conditions in rats. This protocol considered the acinar morphology, i.e., features such as crowding, intraluminal villosities, loss of basal nuclear polarity, and hyperplastic nodules, which were scored according to their degree of severity and distribution pattern. The examination, description, and scoring of the slides were performed in a blinded manner. Histoscores were expressed in arbitrary units and were obtained from a thorough examination of two H&E-stained sections and one hexamine silver-stained section, considering six different fields of vision for samples from each animal.

Quantitative real-time PCR (q-PCR)

Total RNA from the samples was extracted using the Trizol reagent (Invitrogen). The purified RNA samples were quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, DE, USA), and 1 μg of each total RNA sample was reverse transcribed using a PrimeScript™ RT Master Mix (TaKaRa, Dalian, China). The cDNA was subjected to quantitative real-time PCR (q-PCR) analysis to detect the mRNA levels using the SYBR reagent kit (TaKaRa) and QuantStudio™ 6 Flex Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific). All reactions were customized for the specific PCR products and performed in triplicate. The mRNA expression levels of the examined genes were normalized to that of β-actin; the relative mRNA expression levels were calculated using the 2−ΔΔCt method.

Western blotting analysis

The prostatic tissue was ground in liquid nitrogen and the total protein was extracted using a protein extraction kit. Equal amounts (40 μg/lane) of proteins were separated by SDS–polyacrylamide gel electrophoresis; the resultant bands were transferred onto PVDF membranes. After being blocked in 5% bovine serum albumin for 1 h at room temperature, the membranes were incubated with antibodies against TGF-β1 (1:500; Proteintech Group), RhoA (1:5000; Proteintech Group), ROCK1 (1:500; Proteintech Group), and β-actin (1:1000; Affinity Biosciences) overnight at 4 °C. The membranes were washed thrice in TBST for 30 min, and then incubated with horseradish peroxidase-conjugated secondary antibodies (1:5000; Affinity Biosciences) for 1 h followed, by a further washing step for 30 min. Finally, the bands were analyzed using an enhanced chemiluminescence detection system (Pierce; Thermo Fisher Scientific). The data were normalized using β actin as an internal control. All samples were analyzed independently via three repetitions and the mean values were determined.

Assessment of NO, malondialdehyde (MDA), superoxide dismutase (SOD), and ROS

The SOD activity, NO levels, and MDA levels in the prostate tissues were assessed using a superoxide dismutase (SOD) assay kit (WST-1 method), nitric oxide (NO) assay kit (microwell plate method), and malondialdehyde (MDA) assay kit (TBA method), respectively, according to the manufacturer’s instructions. These commercial assay kits were purchased from the Nanjing Jiancheng Bioengineering Institute (Nanjing, Jiangsu, China). The assays were performed in triplicate, and the total protein concentrations were detected to normalize the data. The reactive oxygen species (ROS) generated in situ in the prostate tissues was assessed using DHE-ROS Assay Kit (BestBio Science, Shanghai, China), according to the manufacturer’s instructions. DAPI was used for staining the nuclei. The stained tissues were visualized using a fluorescence microscope.

Statistical analysis

The results were analyzed using GraphPad Prism version 7.04 (GraphPad Software, San Diego, CA, USA) and expressed as the means ± standard deviations (SDs). Differences of the mean values between the three groups were analyzed using one-way ANOVA followed by Tukey’s post hoc multiple comparisons test. For all statistical tests, P values < 0.05 were considered statistically significant.

Results

Effects of the model process on the body weight, prostate weight, and pathological findings in rats

After the completion of the model period, weight-gain was observed in all the groups. Neither hormone nor inflammation significantly affected natural weight-gain. However, the prostate weight increased significantly in the two groups compared with the NC group (Table 1). In addition, we found that the prostates of the EAP group were more prone to bleeding and the prostate capsules partially adhered to the gland, making them hard to remove than the other two groups.

The prostate glands of rats from the NC group were mainly characterized by regular acini tapering into low cuboidal cells showing a uniform, monolayered arrangement. Epithelial lesions were found extensively in samples
from rats in the TI group, such as extensive high columnar epithelia, multiple layers of disordered epithelial cells, even indications of dysplasia including irregular nuclei and loss of cell polarity, while these lesions were mild and limited in samples from rats in the EAP group (Fig. 1b). Occasionally, intraluminal projections protruding into the acini were found in case of the samples from rats in the NC group. Hexamine silver staining was performed to visualize the basement membrane (Fig. 1b). As the projections had a complete basement membrane, they should be considered as the normal infoldings of the alveolar epithelia. However, the samples from rats in the TI and EAP groups showed greater numbers of projections, and some of these projections had an incomplete basement membrane; thus, they should be considered as pathological manifestations.

In the NC group, the acini were embedded within a thin interstitial stroma. However, the samples of the TI and EAP groups showed increased stromal compartments. Furthermore, Masson’s trichrome staining was performed to evaluate the ECM remodeling, which was indicated by collagen deposition. Compared to the other two groups, inflammation induced collagen deposition strongly in the EAP group (Fig. 1c).

Further, a semi-quantitative assessment of the main histopathologic findings was performed using a score-chart protocol to make the pathological examination complete and uniform. Compared to untreated rats, rats in two model groups had higher cumulative histological scores. And the epithelial lesions in rats under hormonal intervention were more severe than the EAP rats; therefore, they had higher scores (Table 2). Moreover, a large number of ki-67 positive cells were found in the epithelial components of the TI group (Fig. 1d), whereas fewer in the EAP group and NC group.

### Significant inflammatory cell infiltration was observed in the samples from rats in the EAP group, with increased expression of multiple cytokines

Based on the HE-stained sections, we analyzed the inflammation degree and percentage of inflammatory foci in the prostate samples from the rats in each group. As the rats of the Wistar strain are sensitive to inflammation [17], there were still some mild inflammatory foci observed in the prostate samples from the rats in the NC group (Fig. 2a).
Samples from some rats in the TI group showed increased inflammatory foci, and samples from two of these rats showed severe inflammatory foci. Samples from almost all rats in the EAP group showed obvious inflammatory infiltration, but those from two rats still failed to show a significant degree of inflammation (the subsequent results in this paper no longer include samples from these two rats within the statistical scope of the data for samples from rats in the EAP group). The success rate of our method with regards to inducing a significant inflammatory response was 77% (n = 7), suggesting the time for the entire modeling process and the dose of the prostate protein extract still needs to improve. In the prostate glands of most rats from the EAP group, severe inflammatory foci were observed in both the stromal and glandular cavity.

The immunohistochemical analysis for the detection of CD3 and CD68 showed that the proportions of T cells and macrophages in the prostate samples from rats in the EAP group were significantly higher compared to the other two groups (Fig. 2b). Q-PCR was performed to analyze the cytokines potentially involved in the crosstalk between inflammatory cells and prostate cells, and we found that the mRNA levels of most cytokines were significantly elevated in the EAP group, at the same time there were relatively small increases of some cytokines in the TI group (Fig. 2c).

**Reactive stroma and activation of the TGF-β/RhoA/ROCK signaling pathway were observed in the samples from the rats in the EAP group**

The immunofluorescence results showed that the expression of α-SMA in the samples from rats in the EAP group was significantly higher than that in the samples from rats in the other two groups (Fig. 3b), indicating the existence of reactive stroma in the samples from rats in the EAP group. The q-PCR and western blotting analyses results show that the expression levels of TGF-β, RhoA, ROCK1, collagen I, and collagen III in samples from rats in the EAP group were higher than those in samples from rats in the TI and NC groups (Fig. 3c, d), indicating that the RhoA/ROCK signaling pathway played an important role in the formation of reactive matrices in the samples from rats in the EAP group.

**Table 2** Histoscore results for the rats from the NC, TI, and EAP groups

| Variable (score values) | NC          | TI          | EAP         |
|-------------------------|-------------|-------------|-------------|
| **Low power magnification** |             |             |             |
| Luminal shape regular (1), villous (3), papillary (4), cribriform (5) | 2.72 ± 0.42 | 4.50 ± 0.58* | 3.44 ± 0.44* |
| Acinar shape tubular (1), branched (3), irregular (5) | 2.78 ± 0.79 | 4.72 ± 0.42* | 4.17 ± 0.82* |
| Interacinar space large or moderate (1), back-to-back glands (5) | 2.11 ± 0.99 | 2.83 ± 1.03 | 3.44 ± 1.42* |
| Stromal: (1), abundant (3), fibrosis/severe SM hyperplasia (5) | 1.22 ± 0.25 | 2.22 ± 0.58* | 3.50 ± 0.53* |
| **High-power magnification** |             |             |             |
| Epithelial shape flattened (1), cuboidal (1), cylindrical (3), hexagonal (5) | 1.78 ± 0.25 | 4.67 ± 0.41* | 2.56 ± 0.60* |
| Number of layers mono(1); oligo, 2−4 (3); pluri, > 5 (5) | 1.39 ± 0.21 | 4.28 ± 0.79* | 2.22 ± 0.63* |
| If>1, add: focal(3), diffuse(5) | 0.89 ± 0.99 | 3.83 ± 0.94* | 3.44 ± 0.83* |
| Alignment polar (1), apolar (3) | 1.83 ± 0.83 | 2.78 ± 0.25* | 2.78 ± 0.34* |
| If there is piling up of epithelial cells, add 3 | 1.11 ± 0.52 | 2.17 ± 1.18* | 2.72 ± 0.42* |
| If there is budding out of epithelial cells into stroma, add 5 | 0.00 ± 0.00 | 1.83 ± 1.05* | 0.44 ± 0.50* |
| If periacinar clusters of epithelial cells are found, add 3 | 0.33 ± 0.47 | 1.44 ± 0.64* | 2.56 ± 0.93* |
| If isolated clusters of epithelial cells are found outside acini, add 5 | 0.22 ± 0.42 | 2.00 ± 1.18* | 0.94 ± 0.96* |
| Lesion distribution (for apolar or budding out cells, no lesion = 0): unilobar: isolated (2), multiple (6). bilobar: isolated (4), multiple (8) | 1.72 ± 0.71 | 7.11 ± 1.66* | 6.22 ± 1.99* |
| Nuclear shape round, regular (1); irregular (5) | 1.00 ± 0.00 | 1.83 ± 0.67 | 1.00 ± 0.00 |
| Nuclear size small (2), large (2), small and large in the same acinus (4) | 1.11 ± 0.21 | 2.39 ± 0.46* | 1.33 ± 0.53* |
| Mitoses per field absent (0); isolated, 1–2 (2); abundant, 3–5 (5); excessive, > 5 (10) | 0.00 ± 0.00 | 2.33 ± 0.41* | 0.33 ± 0.62* |
| Basement membrane intact (1); interrupted (5) | 1.17 ± 0.24 | 2.56 ± 0.80* | 1.22 ± 0.42* |
| Thin (1); thick (5) | 1.50 ± 0.41 | 3.83 ± 0.91* | 3.83 ± 0.91* |
| Total score (arbitrary units) | 22.89 ± 1.93 | 57.33 ± 3.47* | 46.17 ± 5.33* |

Values are expressed as the means ± S.D. *Significant difference compared to the NC group, P < 0.05; †significant difference compared to the TI group, P < 0.05
Enhanced oxidative stress, but no obvious oxidative damage was observed in the samples from rats in the EAP group

The immunofluorescence results showed that the ROS production in the samples from the rats in the EAP and TI groups was significantly higher than that in the samples from the rats in the NC group. The expression levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) (q-PCR results; Fig. 2c), and the NO production levels (ELISA results) in the samples from the rats in the EAP and TI groups were higher than those in the samples from the rats in the NC group. With regards to the antioxidant activity, the SOD activity in the samples from the rats in the EAP group was significantly higher than that in the samples from the rats in the NC and TI groups. With regards to oxidative damage, a lesser amount of MDA, which is a genotoxic lipid peroxide, was generated in the samples from the rats in the EAP group than in those from the rats in the TI group (Fig. 4).

Discussion

The BPH nodules of individual patients are composed of distinct cell types, and pathological heterogeneity is an underappreciated confounder to identifying novel drug target [19]. Causative molecular pathways involved in a specific BPH phenotype require in-depth research. Our experimental study found that chronic prostatitis induced by autoimmune method in rats showed heterogeneous prostatic hyperplasia from conventional hormone model methods. The EAP rats showed increased stroma compartments and reactive epithelial hyperplasia, while testosterone caused severe epithelial hyperplasia or even atypical hyperplasia.

Many lines of evidence have supported that androgens are permissive, but insufficient for the induction of BPH [20]. The incidence of BPH increases with age in human, but the serum testosterone levels decrease [14]. Androgen supplementation in men does not appear to increase the risk of incident BPH or LUTS (lower urinary tract symptoms) [21, 22]. In the past nearly 50 years, researchers are accustomed...
to using large doses of testosterone to induce BPH in animal experiments as hormones can quickly and easily induce significant prostate epithelial hyperplasia in young animals. However, it has limitations: (1) the theoretical basis of the hormone-induced model is that the proportion of estrogen and androgen increases with age [20], while disregarding the role of other factors such as inflammation in BPH. (2) Exogenous hormones strongly destroy the hormonal balance of young animals, affecting the immune state of the prostate, as the prostate is also a potential immune organ [23]. (3) Because of the inconsistency of the hormone model induction method, the final pathological status of BPH is not uniform. In particular, there are no consistent reports on whether significant proliferation in the prostatic stroma is observed. For example, some studies reported stromal lesions [11, 12, 24], whereas others only reported epithelial lesions [10, 13, 25–28]. Taken together, the traditional method of hormone-induced model has some limitations in the study of BPH-related mechanism and treatment. Therefore, a new method of induction of hormone-induced model is worthy exploring.

There is already numerous clinical evidence supporting the correlation between BPH and inflammation [5–7]. Many in vitro and in vivo studies have indicated that the activation and dysregulation of prostatic immune cells, and the release of several cytokines and growth factors including IL-2, IL-4, IL-6, IL-17, fibroblast growth factor 2 (FGF-2), were both associated with the initiation and progression of BPH [23]. We found a sharp increase for the size of the stromal compartment in the prostates from EAP rats, accompanied by elevated mRNA levels of several cytokines that stimulated the growth of stromal cells, such as IL-2, IL-4, IL-17, and IL-18 [23]. Franiel et al. [29] reported that areas of chronic prostatitis tissues had a larger stromal volume than areas of normal prostate tissues. The mean stroma-to-epithelium ratio in the prostate adenomas from men with symptomatic BPH is also higher than that in those from asymptomatic patients [30]. Therefore, inflammation may be a key factor affecting the stromal compartment in both humans and rats, even further promote symptomatic BPH. Unlike rats with chronic prostate inflammation, our research found that large dose of hormone strongly cause epithelial

![Figure 3](image-url)

**Fig. 3** Reactive stroma and levels of the TGF-β/RhoA/ROCK signaling pathway-related components in the prostate samples. **a** IHC staining for detecting TGF-β1 in the rat prostate samples. The black pentagram indicates TGF-β1-positive infiltrating inflammatory cells. **b** Upper panel, IF staining for detecting α-SMA (green) in the rat prostate samples. DAPI staining was performed to detect the nuclei (blue). Lower panel, merging of the α-SMA-stained and nucleus-stained images. **c** The relative mRNA expression levels of the TGF-β1, α-SMA, RhoA, ROCK1, and collagen genes obtained by q-PCR. **d** Representative western blotting results of the TGF-β1, RhoA, and ROCK1 levels in the prostate samples. The graph below indicates the relative densitometric quantification of the proteins. Results are expressed as the ratio of the density of each protein band to the ratio of the density of the β-actin band. Each bar in the graphs represents the mean ± S.D. *Significant difference compared to the NC group, \( P<0.05 \); #significant difference compared to the TI group, \( P<0.05 \).
hyperplasia, even atypical hyperplasia in rats. This may be due to the DNA damage induced by serious oxidative stress in the prostate tissues of TI rats. Oxidative stress is commonly observed in hormone-induced BPH models [13, 25, 26], and elevated HIF-1α means significant hypoxia in the model group [24]. However, there was no increase in the MDA levels in the EAP group, because the elevated SOD limited the detrimental effect from ROS. Correspondingly only moderate epithelial hyperplasia was observed in the EAP group. Overall, our results suggested that inflammation and hormones induced heterogeneous BPH in the rat model through different mechanisms.

Recent studies have revealed inflammation implicated as a cause of prostatic fibrosis that contributes to bladder outlet obstruction [31]. Fibrosis in BPH is promoted by the activation of excessive α-SMA-expressing myofibroblasts, which are differentiated from fibroblasts during chronic inflammation and deposit ECM components [32, 33]. TGF-β1 can upregulate the activation of the RhoA/ROCK pathway, promoting cytoskeletal rearrangement and ultimately inducing fibroblast-to-myofibroblast differentiation [34]. In our experiments, elevated TGF-β1 in EAP rats led to activation of RhoA/ROCK pathway and fibrosis of the prostate.

Fig. 4 Indicators reflecting the oxidative stress in the prostate samples. a ROS produced in situ was assessed using the fluorescent probe DHE. b NO concentrations in samples from rats in all the groups. c SOD activity in samples from rats in all the groups (assessed using an assay kit: WST-1 method). d MDA concentrations in samples from rats in all the groups. Each bar in the graphs represents the mean ± S.D. *Significant difference compared to the NC group, $P<0.05$; #Significant difference compared to the TI group, $P<0.05$.
prostate, while rats under hormonal intervention did not undergo this process.

Autoimmune response, one of the main causes of chronic prostatitis [35-39], is also considered to be as a trigger for the dysregulation of the prostatic immune system and results in the development of BPH nodules [23]. Activated by autoantigens, such as prostate steroid-binding protein, T lymphocytes play a key role as effector and helper cells in the cell-mediated immune response [38, 40]. Besides, prostate cells also released cytokines forming a prostatic network that affect the prostatic proliferation [41]. For example, IL17 mainly from T lymphocytes, activates the NFκB pathway, regulates the expression of IL-6, IL-8, and IL-1 in epithelial and stromal cells, and upregulates the expression of COX2 in macrophages and epithelial cells [23]. COX-2 suppresses the apoptosis by enhancing the expression of anti-death proteins [24]. IL-2, IL-4, and IL-18 stimulate the proliferation of stromal cells. IL-8 induces paracrine of FGF-2 in stromal cells. In our experiment, the inflammatory factor network was examined initially by q-PCR, but further experiments were needed to explore the detailed associations.

Notably, the rats with testosterone administration also showed evidence of inflammatory infiltration compared with the NC group, which might be due to two reasons different from the EAP group. On the one hand, hypoxia and oxidative stress are both observed in hormone-induced BPH rat models and oxidative stress can activate the NFκB signaling pathway, known as an important inflammatory transcriptional regulator [42]. Abnormal ROS affect the activities of inflammatory mediators and cellular processes involved in the initiation, promotion, and progression of human neoplasms, including BPH and prostate cancer [43]. On the other hand, androgens can be metabolized to estrogens locally within the prostate via the aromatase enzyme [44]. Over-activated aromatase in transgenic mice leads to obstructive voiding [11]. Aromatase inhibitor administered to beagles treated with testosterone and androstenedione, inhibited hormone-induced prostate growth [20]. Testosterone also reduces ER-β and enhances ER-α expression [45], and ER-α stimulation in the prostate results in hyperplasia, inflammation, and dysplasia [20]. In addition, estrogens activate an inflammatory response through the activation of the nonclassical G-protein-coupled estrogen receptor 1, increasing expression of IL-8 [46]. The development of inflammation in response to estrogen is independent of androgens and is the direct response of the prostate to estrogens [44]. Thus, although testosterone alone was administered in our study, the prostates in the TI rats were still affected by endogenous estrogen and developed inflammatory infiltration. Further, the complex metabolism of sex hormones in the prostate makes it difficult to explain the detail mechanism for drug experiment using a hormone-induced BPH model.

In summary, the induction of inflammation can promote the proliferation of prostatic epithelia and stroma, and the effect of inflammation on the stroma is more significant than that of testosterone-induced epithelial changes in rats. In the inflammatory state, increased TGF-β levels contribute to the transdifferentiation of prostate fibroblasts into myofibroblasts, and deposition of new ECM, promoting fibrosis in the prostate gland, in which RhoA/ROCK signaling plays an important role. In study of the therapeutic effects of drugs on stroma components during BPH, we recommend the use of the EAP model, which qualifies as a model of BPH and aids the understanding of the mechanisms underlying inflammation in BPH.

Author contributions ZC and KC: project development and manuscript editing. CL and TX: data collection and data analysis. ZM: project development, data collection, data analysis, and manuscript writing. All authors have contributed to and approved the final manuscript.

Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Natural Science Foundation of China (Grant Number 81873625, China). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Compliance with ethical standards

Conflict of interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Research involving human participants and/or animal Our research involves just Wistal rats. It was animal experiment.

Informed consent Throughout the animal experiment, we applied the appropriate procedures approved by the Institutional Animal Care and Use Committee of the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Hubei, China).

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Ekman P (1989) BPH epidemiology and risk factors. Prostate Suppl 2:23–31. https://doi.org/10.1002/pros.2900150505

2. Roehrborn CG (2008) Pathology of benign prostatic hyperplasia. Int J Impot Res 20(Suppl 3):S11–18. https://doi.org/10.1038/ijir.2008.55

3. Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F (2013) The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 112(4):432–441. https://doi.org/10.1111/bju.12118

4. Kohnen PW, Drach GW (1979) Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol 121(6):755–760. https://doi.org/10.1016/s0022-5347(17)36980-3

5. Wu ZL, Yuan Y, Geng H, Xia SJ (2012) Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl 14(2):316–319. https://doi.org/10.1111/j.1464-1704.2007.00910.x

6. Bostanci Y, Kazzazi A, Montahen S, Laze D, Djavan B (2013) Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 23(1):5–10. https://doi.org/10.1097/MOU.0b013e32835ab44a

7. Sun F, Baey-Diaz C, Sanchez-Margallo FM (2017) Canine prostate models in preclinical studies of minimally invasive interventions: part II, benign prostatic hyperplasia models. Transl Androl Urol 6(3):547–555. https://doi.org/10.21037/tau.2017.03.62

8. Park BK, Kim CW, Kwon JE, Negi M, Koo YT, Lee SH, Baek DH, Koh YH, Kang SC (2019) Effects of Lespedeza cuneata aqueous extract on testosterone-induced prostatic hyperplasia. Pharm Biol 57(1):90–98. https://doi.org/10.1080/13880209.2018.1564929

9. Kwon MO, Kim YS, Cho YJ, Park YH, Park DJ, Wanka S, Yang Y, Shin H, Jeong S, Kim JH (2019) Characterization of a model of prostatic diseases and obstructive voiding induced by sex hormone imbalance in the Wistar and Noble rats. Transl Androl Urol 8(Suppl 1):S45–S57. https://doi.org/10.21037/tau.2019.02.03

10. Miao L, Jiao C, Shao R, Qi Y, Fan G, Li X, Wang Y, Zhu Y, Zhang J, Gao X (2019) Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor beta and down-regulation of stromal aromatase. Toxicol Appl Pharmacol 381:114637. https://doi.org/10.1016/j.taap.2019.114637

11. Jeon WY, Kim OS, Seo CS, Jin SE, Kim JA, Shin HK, Kim YU. Lee MY (2017) Inhibitory effects of Poncirus Fructus on testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med 17(1):384. https://doi.org/10.1186/s12906-017-1877-y

12. Huhtaniemi I (2014) Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J Androl 16(2):192–202. https://doi.org/10.1111/ajm.122336

13. Zhou XH, Li LD, Wu LM, Han L, Liu ZD, Yang JX, Lv YW, You CL, Zhou ZH (2007) Increased inflammatory factors activity in model rats with experimental autoimmune prostatitis. Arch Androl 53(2):49–52. https://doi.org/10.1080/01485010600908397

14. Cui K, Luany T, Fang K, Wang T, Chen Z, Wang S, Liu J, Wang D (2017) Involvement of DDAH/ADMA/NOS/cGMP and COX-2/PGTS/cAMP pathways in human tissue Kallikrein 1 protecting erectile function in aged rats. Plone ONE 12(1):e0170427. https://doi.org/10.1371/journal.pone.0170427

15. Scolnik MD, Servadio C, Abramovic A (1994) Comparative study of experimentally induced benign and atypical hyperplasia in the ventral prostate of different rat strains. J Androl 15(4):287–297

16. Golomb E, Rosenzweig N, Eilam R, Abramovici A (2000) Spon- taneous hyperplasia of the ventral lobe of the prostate in aging genetically hyperensive rats. J Androl 21(1):58–64

17. Strand DW, Costa DN, Francis F, Ricke WA, Roehrborn CG (2017) Targeting phenotypic heterogeneity in benign prostatic hyperplasia. Differentiation 96:49–61. https://doi.org/10.1016/j. diff.2017.07.005

18. Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82(4–5):184–199. https://doi.org/10.1016/j.diff.2011.04.006

19. Davies P, Eaton CL (1991) Regulation of prostate growth. J Endocrinol 131(1):5–17. https://doi.org/10.1677/joe.0.1310005

20. Morales A (2002) Androgen replacement therapy and prostate safety. Eur Urol 41(2):113–120. https://doi.org/10.1016/s0302-2838(01)00039-2

21. De Nunzio C, Presicce F, Tubaro A (2016) Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 13(10):613–626. https://doi.org/10.1038/nnurol.2016.168

22. Zhou J, Lei Y, Chen J, Zhou X (2018) Potential ameliorative effects of epigallocatechin 3 gallate against testosterone-induced benign prostatic hyperplasia and fibrosis in rats. Int Immunopharmacol 64:162–169. https://doi.org/10.1016/j.intimp.2018.08.038

23. Jena AK, Vashiik S, Sharma N, Kaur R, Dhingra MS, Karan M (2016) Amelioration of testosterone induced benign prostatic hyperplasia by Prunus species. J Ethnopharmacol 190:33–45. https://doi.org/10.1016/j.jep.2016.05.052

24. Ishola IO, Tijani HK, Dosumu OO, Anunobi CC, Oshodi TO (2017) Atorvastatin attenuates testosterone-induced benign prostatic hyperplasia in rats: role of peroxisome proliferator-activated receptor-gamma and cyclo-oxygenase-2. Fundam Clin Pharmacol 31(6):652–662. https://doi.org/10.1111/fcp.12301

25. Yang X, Yuan L, Xiong C, Yin C, Ruan J (2014) Abacopteris pendaniana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol 190:33–45. https://doi.org/10.1016/j.jep.2016.05.052

26. Lee G, Shin J, Choi H, Jo A, Pan S, Bae D, Lee Y, Choi C (2017) Cynanchum wilfordii ameliorates testosterone-induced benign prostatic hyperplasia by regulating 5α-reductase and androgen receptor activities in a rat model. Nutrients. https://doi.org/10.3390/nu9101070

27. Faniel T, Ludemann L, Rudolph B, Rehbein H, Stephan C, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331. https://doi.org/10.1111/j.1464-1704.2007.00910.x

28. Lee G, Shin J, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331. https://doi.org/10.1111/j.1464-1704.2007.00910.x

29. Franel T, Ludemann L, Rudolph B, Rehbein H, Stephan C, Motiwala HG, Laniado ME (2007) Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia? BJU Int 100(2):327–331. https://doi.org/10.1111/j.1464-1704.2007.00910.x

30. Shapiro E, Becich MJ, Hartanto V, Lepor H (1992) The relative proportion of stromal and epithelial hyperplasia is related to the proportion of stromal and epithelial hyperplasia. Asian J Androl 53(2):49–52. https://doi.org/10.1080/01485010600908397

31. Bushman WA, Jerde TJ (2016) The role of prostate inflammation and fibrosis in lower urinary tract symptoms. Am J Physiol

32. Springer
32. Sampson N, Berger P, Zenzmaier C (2012) Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev 2012:458276. https://doi.org/10.1155/2012/458276

33. Amano M, Nakayama M, Kaibuchi K (2010) Rho-kinase/ROCK: a key regulator of the cytoskeleton and cell polarity. Cytoskeleton (Hoboken) 67(9):545–554. https://doi.org/10.1002/cm.20472

34. Kardassis D, Murphy C, Fotsis T, Moustakas A, Stournaras C (2009) Control of transforming growth factor beta signal transduction by small GTPases. FEBS J 276(11):2947–2965. https://doi.org/10.1111/j.1742-4658.2009.07031.x

35. Hou Y, DeVoss J, Dao V, Kwek S, Simko JP, McNeel DG, Anderson MS, Fong L (2009) An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest 119(7):2031–2041. https://doi.org/10.1172/JCI38332

36. Motrich RD, Maccioni M, Molina R, Tissera A, Olmedo J, Riera CM, Rivero VE (2005) Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol 116(2):149–157. https://doi.org/10.1016/j.clim.2005.03.011

37. Motrich RD, Maccioni M, Ponce AA, Gatti GA, Oberti JP, Rivero VE (2006) Pathogenic consequences in semen quality of an autoimmune response against the prostate gland: from animal models to human disease. J Immunol 177(2):957–967. https://doi.org/10.4049/jimmunol.177.2.957

38. Bresee ML, Motrich RD, Sanchez LR, Mackern-Oberti JP, Rivero VE (2013) Expression of CXCR3 on specific T cells is essential for homing to the prostate gland in an experimental model of chronic prostatitis/chronic pelvic pain syndrome. J Immunol 190(7):3121–3133. https://doi.org/10.4049/jimmunol.1202482

39. Maccioni M, Rivero VE, Riera CM (1998) Prostatein (or rat prostatic steroid binding protein) is a major autoantigen in experimental autoimmune prostatitis. Clin Exp Immunol 112(2):159–165. https://doi.org/10.1046/j.1365-2249.1998.00588.x

40. Depiante-Depaoli M, Pacheco-Rupil B, Britos S, Casas A (1984) Experimental autoimmune damage to rat male accessory glands I Transfer of autoimmune response by spleen cells. Am J Reprod Immunol 5(1):9–14. https://doi.org/10.1111/j.1600-0897.1984.tb00280.x

41. Fibi B, Penna G, Morelli A, Adorini L, Maggi M (2010) Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int J Androl 33(3):475–488. https://doi.org/10.1111/j.1365-2605.2009.00972.x

42. Minciullo PL, Inferrera A, Navarra M, Calapai G, Magni C, Gangemi S (2015) Oxidative stress in benign prostatic hyperplasia: a systematic review. Urol Int 94(3):249–254. https://doi.org/10.1159/000366210

43. Chang WH, Tsai YS, Wang JY, Chen HL, Yang WH, Lee CC (2019) Sex hormones and oxidative stress mediated phthalate-induced effects in prostatic enlargement. Environ Int 126:184–192. https://doi.org/10.1016/j.envint.2019.02.006

44. Ellem SJ, Risbridger GP (2009) The dual, opposing roles of estrogen in the prostate. Ann NY Acad Sci 1155:174–186. https://doi.org/10.1111/j.1749-6632.2009.04360.x

45. Wu X, Gu Y, Li L (2017) The anti-hyperplasia, anti-oxidative and anti-inflammatory properties of Qing Ye Dan and swertiamarin in testosterone-induced benign prostatic hyperplasia in rats. Toxicol Lett 265:9–16. https://doi.org/10.1016/j.toxlet.2016.11.011

46. Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119. https://doi.org/10.1038/nruro.2015.301

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.